ALT
Altimmune Inc
3.30$
+0.3%
vs. previous close
Closing price · As of: Sep 18, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | – | 100.0% | 100.0% | 100.0% | |
| 41.9% | 47.6% | 138.1% | 44,349.4% | 178.7% | 294.2% | 409.4% | 1,674.4% | – | 112.0% | 1,190.0% | 273.2% | |
| 58.1% | 52.4% | -38.1% | -44,249.4% | -78.7% | 100.0% | -309.4% | 100.0% | – | 100.0% | 100.0% | 100.0% | |
| 91.5% | 48.2% | 92.5% | 44,349.4% | 178.7% | 306.2% | 608.1% | 1,690.3% | – | 15,445.8% | 411,130.0% | 162,029.3% | |
| 107.1% | 58.5% | 220.2% | 20,378.2% | 94.5% | 146.5% | 161.4% | 349.5% | – | 4,257.5% | 104,830.0% | 68,531.7% | |
| 200.0% | 108.1% | 315.4% | 38,954.0% | 273.2% | 470.0% | 360.1% | 2,297.6% | – | 22,618.5% | 515,960.0% | 230,561.0% | |
| -100.0% | -32.0% | -215.4% | -125,401.2% | -414.6% | -370.0% | -669.5% | -2,197.6% | – | -22,518.5% | -515,860.0% | -230,461.0% | |
| 2.1% | 0.5% | 0.7% | 390.7% | 2.9% | 0.0% | 0.1% | 0.1% | – | 8.2% | 45.0% | 3,990.2% | |
| -97.1% | -31.8% | 3,920.0% | -125,445.8% | -438.7% | -354.7% | -533.0% | -2,201.6% | – | -20,762.2% | -475,295.0% | -216,522.0% | |
| 0.6% | 0.6% | 213.6% | -13,585.5% | -59.5% | -1.0% | 66.2% | -20.9% | – | 72.6% | – | -1,661.0% | |
| -97.7% | -32.3% | 3,706.4% | -111,860.3% | -379.2% | -353.7% | -599.2% | -2,201.6% | – | -20,762.2% | -475,295.0% | -214,861.0% | |
| -93.5% | -29.9% | -208.7% | -124,720.2% | -432.9% | -348.0% | -465.5% | -2,189.0% | – | -20,642.0% | -474,060.0% | -212,258.5% |
Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.